Targeting AXL in NSCLC
Aubhishek Zaman,1,2 Trever G Bivona1,2 1Department of Medicine, University of California, San Francisco, CA, USA; 2UCSF Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USACorrespondence: Trever G Bivona Email trever.bivona@ucsf.eduAbstract: State-of-the-art can...
Guardado en:
Autores principales: | Zaman A, Bivona TG |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/01e16318a1f14041832b1e2fd09330bd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
AXL receptor tyrosine kinase as a therapeutic target in NSCLC
por: Okimoto RA, et al.
Publicado: (2015) -
Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer
por: Dan Yan, et al.
Publicado: (2021) -
Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers
por: Stratmann JA, et al.
Publicado: (2019) -
AXL receptor is required for Zika virus strain MR-766 infection in human glioblastoma cell lines
por: Samuel D. Zwernik, et al.
Publicado: (2021) -
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick O, et al.
Publicado: (2021)